The pure antiestrogen ICI 182,780 inhibits progestin-induced transcription

Cancer Research

Volumn 59, Issue 2, 1999, Pages 372-376

  Nawaz, Zafar ^a   Stancel, George M ^b   Hyder, Salman M ^b,c  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; GESTAGEN; METRIBOLONE; MIFEPRISTONE; TAMOXIFEN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CONCENTRATION RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HELA CELLS; HUMANS; PROGESTINS; TRANSCRIPTION, GENETIC;

EID: 0033556050     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Beatson, G. T. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases. Lancet, 2: 104-107, 1896.
2. Gradishar, W. J., and Jordan, V. C. Clinical potential of new antiestrogens. J. Clin. Oncol., 15: 840-852, 1997.
3. Katzenellenbogen, B. S., Montano, M. M., Ekena, K., Herman, M. E., and McInerney, E. M. Antiestrogens: mechanisms of action, and resistance in breast cancer. Breast Cancer Res. Treat., 44: 23-38, 1997.
4. Jordan, V. C. Tamoxifen for breast cancer prevention. Proc. Soc. Exp. Biol. Med., 208: 144-149, 1995.
5. Jordan, V. C. Third annual William L. McGuire memorial lecture: studies on the estrogen receptor in breast cancer - 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res. Treat., 36: 267-285, 1995.
6. Wiebe, V. J., Osborne, C. K., Fuqua, S. A. W., and DeGregorio, M. W. Tamoxifen resistance in breast cancer. Crit. Rev. Oncol. Hematol., 14: 173-188, 1993.
7. Parker, M. G. Action of "pure" antiestrogens in inhibiting estrogen receptor action. Breast Cancer Res. Treat., 26 131-137, 1993.
8. Johnston, S. R. Acquired tamoxifen resistance in human breast cancer: potential mechanisms and clinical implications. Anticancer Drugs, 8: 911-930, 1997.
9. Levenson, A. S., Catherino, W. H., and Jordan, V. C. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor. J. Steroid Biochem. Mol. Biol., 60: 261-268, 1997.
10. Wakeling, A. E. Tissue-specific actions of antioestrogens. Mutat. Res., 333: 45-49, 1995.
11. Hyder, S. M., Stancel, G. M., Chiappetta, C., Murthy, L., Boettger-Tong, H. L., and Makela, S. Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Res., 56: 3954-3960, 1996.
12. Hyder, S. M., Chiappetta, C., and Stancel, G. M. Triphenylethylene antiestrogens induce uterine vascular endothelial growth factor expression via their partial estrogen agonist activity. Cancer Lett., 120: 165-171, 1997.
13. Howell, A., and Robertson, J. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, 345: 989-990, 1995.
14. DeFriend, D. J., Howell, A., Nicholson, R. I., Anderson, E., Dowsett, M., Mansel, R. E., Blamey, R. W., Bundred, N. J., Robertson, J. F., Saunders, C., Baum, M., Walton, P., Sutcliffe, F., and Wakeling, A. E. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res., 54: 408-414, 1994.
15. Hu, X. F., Veroni, M., De Luise, M., Wakeling, A., Sutherland, R., Watts, C. K., and Zalcberg, J. R. Circumvention of tamoxifen resistance by the pure anti-estrogen ICI 182, 780 Int. J. Cancer. 55: 873-876, 1993.
16. Weiss, D. J., and Gurpide. E. Non-genomic effects of estrogens and antiestrogens. J. Steroid Biochem., 31: 671-676, 1988.
17. Hisson, J. R., Bowden, R. T., and Moore, M. R. Effects of progestin, estrogens, and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D. Endocrinology, 125: 418-423, 1989.
18. Teutsch, G., and Philibert, D. History and perspectives of antiprogestins from the chemist's point of view. Hum Reprod. (Oxf.). 9 (Suppl. 1): 12-31, 1994.
19. Allan, G. F., Leng, X., Tsai, S. T., Weigel, N. L., Edwards, D. P., Tsai, M. J., and O'Malley, B. W. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J. Biol. Chem., 267: 19513-19520, 1992.
20. Vegeto, E., Allan, G. F., Schrader, W. T., Tsai, M. S., McDonnell, D. P., and O'Malley, B. W. The mechanism of RU-486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. Cell. 69: 703-713, 1992.
21. Tilley, W. D., Marcelli, M., Wilsom, J. D., and McPhaul, M. M. Characterisation and expression of a cDNA encoding the human androgen receptor. Proc. Natl. Acad. Sci. USA, 86: 327-331, 1989.
22. Beato, M. Gene regulation by steroid hormone receptors. Cell, 56: 335-344, 1989.
23. Hyder, S. M., Stancel, G. M., Nawaz, Z., McDonnell, D. P., and Loose-Mitchell, D. S. Identification of an estrogen response element in the 3′-flanking region of the murine c-fos protooncogene. J. Biol. Chem., 267: 18047-18054, 1992.
24. Spencer, T. E., Jester, G., Burcin, M. M., Allis, C. D., Zhou, J. X., Mizzen, C. A., McKenna, N. J., Onate, S. A., Tsai, S. Y., Tsai, M. J., O'Malley, B. W. Steroid receptor co-activator-1 is a histone acetyltransferase Nature 389: 194-198, 1997.
25. Duax, W. L., Griffin, J. F., Weeks, C. M., and Wawrzak, Z. The mechanism of action of steroid antagonists: insights from crystallographic studies. J. Steroid Biochem., 31: 481-492, 1988.
26. Dauvois, S., White, R., and Parker, M. G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci., 106: 1377-1388, 1993.
27. Wilson, J. W., Wakeling, A. E., Morris, I. D., Hickman, J. A., and Dive, C. Regulation of progesterone receptor messenger ribonucleic acid in the rat medial preoptic nucleus by estrogenic and antiestrogenic compounds: an in situ hybridization study. Endocrinology. 138: 5476-5484, 1997.
28. Wakeling, A. E., and Bowler, J. Biology and mode of action of pure antiestrogens. J. Steroid Biochem., 30: 141-147, 1988.
29. Pasqualini, J. R., and Gelly, C. Biological response of the anti-estrogen ICI 164 384 in hormone-dependent and hormone-independent mammary cancer cell lines. Cancer Lett., 50: 133-139, 1990.
30. Jamil, A., Croxtall, J. D., and White, J. O. The effect of anti-oestrogens on cell growth and progesterone receptor concentration in human endometrial cancer cells (Ishikawa). J. Mol. Endocrinol., 6: 215-221, 1991.
31. Sadovsky, Y. Kushner, P. J., Roberts, J. M., and Riemer, R. K. Restoration of estrogen-dependent progesterone receptor expression in a uterine myocyte cell ine. Endocrinology, 132: 1609-1613, 1993.
32. Parisot, J. P., Hu, X. F., Sutherland, R. L., Wakeling, A., Zalcberg, J. R., and DeLuise, M. The pure antiestrogen ICI 182, 780 binds to a high-affinity site distinct from the estrogen receptor. Int. J. Cancer, 62: 480-484, 1995.
33. Pavlik, E. J., Nelson, K., Srinavas, S., Meares, K., Van Nagell, K., Depriest, P D., Gallion, H. S., Van Nagell, J. R., III, and Kenady, D. E. The pure antiestrogen ICI 164,384 interacts with estrogen receptors and non-estrogen receptor molecules in rodent and human preparations. Endocr. J., 1: 147-155, 1993.
34. Weaver, C. A., Springer, P. A., and Katzenellenbogen, B. S. Regulation of pS2 gene expression by affinity labeling and reversibly binding estrogens and antiestrogens: comparison of effects on the native gene and on pS2-chloramphenicol acetyl transferase fusion genes transfected into MCF-7 human breast cancer cells. Mol. Endocrinol. 2: 936-945, 1988.